References
- Bayer O., Kolmer D., Doukas Ch. Zur Genese der Herzklappenveränderungen beim Karzinoid-syndrom. Dtsch Med Wschr 1966; 91: 1217
- Crawford N. The lungs and serotonin metabolism: A study of the pulmonary arterio-venous of plasma free and platelet-bound serotonin in man. Clin Chim Acta 1965; 12: 264
- Gaddum J. H., Hebb C. O., Silver A., Swan A. A. B. 5-hydroxytryptamine. Pharmacological action and destruction in perfused lungs. Quart J Exp Phy-siol 1953; 38: 255
- Goble A. J., Hay D. R., Sandier M. 5-hydroxytryptamine metabolism in acquired heart-disease associated with argentaffin carcinoma. Lancet 1955; 269: 1016
- Hallen A. Fibrosis in the carcinoid syndrome. Lancet 1964; I: 746
- Heikkinen E. S. Biological inactivation of 5-hydroxytryptamine. Experimental study on rats., To be published.
- Hughes F. B., Brodie B. B. The mechanism of serotonin and catecholamine uptake by platelets. J Pharmacol Exper Ther 1959; 127: 96
- Klingman G. J. Monoamine oxidase activity of peripheral organs and sympathetic ganglia of the rat after immunosympathectomy. Biochem Pharmac 1966; 15: 1729
- Page J. H. 5-hydroxytryptamine. Proceedings of a symposium held in London on 1st and 2nd April 1957. Pergamon Press Ltd, Belfast. 1958; 93
- Thorson Å. H. Studies on carcinoid disease. Acta Med Scand 1958; 161, Suppl. 334
- Waalkes T. P. The determination of serotonin (5-hydroxytryptamine) in human blood. J Lab Clin Med 1959; 53: 824